Table 4. Associations between tertiles of dietary iron intake and breast cancer risk from multivariable cox proportional hazards models, stratified by antioxidant/placebo group of the SU.VI.MAX trial and by lipid intake,france, 1994–@2007a, b, c.
| Placebo group | Antioxidant supplementation group | |||||
|---|---|---|---|---|---|---|
| N for cases/non-cases | HR (95% CI) | P-trend | N for cases/non-cases | HR (95% CI) | P-trend | |
| Total lipid intake < median (78.5 g/d) | 0.1 | 0.3 | ||||
| Tertile 1 | 20/632 | 1.00 | 21/602 | 1.00 | ||
| Tertile 2 | 18/338 | 1.58 (0.76, 3.24) | 12/345 | 0.94 (0.41, 2.15) | ||
| Tertile 3 | 12/143 | 1.99 (0.79, 4.99) | 11/169 | 1.67 (0.63, 4.42) | ||
| Total lipid intake ≥ median (78.5 g/d) | 0.046 | 0.2 | ||||
| Tertile 1 | 5/140 | 1.00 | 7/121 | 1.00 | ||
| Tertile 2 | 15/413 | 1.41 (0.49, 4.06) | 12/396 | 0.40 (0.15, 1.05) | ||
| Tertile 3 | 30/576 | 2.57 (0.86, 7.68) | 25/583 | 0.42 (0.15, 1.17) | ||
CI, confidence interval, HR, Hazard ratio, SU.VI.MAX, Supplémentation en Vitamines et Minéraux Antioxydants
a
Multivariable models were adjusted for age (timescale), energy intake without alcohol, intervention group of the initial SU.VI.MAX trial, number of 24-h dietary records, smoking status, educational level, physical activity, height, BMI, alcohol intake, family history of breast cancer, lipids intake, use of hormone replacement therapy, and number of children.
b Cut-offs for tertiles of dietary iron intake were 9.3 and 11.9 mg/d.
c P for interaction between dietary iron and lipid intakes: Placebo group, 0.3; Antioxidant supplementation group, 0.5.